13 Results for "

PPT1

" in MedChemExpress (MCE) Product Catalog:
Products (13)

13 Results for "PPT1" in MCE Product Catalog:

  • Isoforms Recommended:
6
6 Publications Verification
Cat. No.: HY-111621
CAS No.: 1872387-43-3
Purity:  99.53%
Target:  

Autophagy Apoptosis

Research Areas:  

Cancer

DC661 is a potent palmitoyl-protein thioesterase 1 (PPT1) inhibitor, inhibits autophagy, and acts as an anti-lysosomal agent. Anti-cancer activity [1].
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-137978A
CAS No.: 1914148-73-4
Purity:  99.29%
Synonyms: GNS561 hydrochloride
Ezurpimtrostat hydrochloride (GNS561 hydrochloride) is an orally active PPT1 inhibitor, autophagy inhibitor, immunomodulator, anti-inflammatory agent, and anticancer agent. Ezurpimtrostat hydrochloride inhibits PPT1, dysregulates lysosomal function, redistributes mTOR, and induces apoptosis. Ezurpimtrostat hydrochloride reduces IFN‑α, CRP, immune complex deposition, and SARS‑CoV‑2 viral load. Ezurpimtrostat hydrochloride can be used for the study of systemic lupus erythematosus, SARS‑CoV‑2, hepatocellular carcinoma, fibrosis, and related disorders [1] .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-137978
CAS No.: 1914148-72-3
Synonyms: GNS561
Ezurpimtrostat (GNS561) is an orally active PPT1 inhibitor, autophagy inhibitor, immunomodulator, anti-inflammatory agent, and anticancer agent. Ezurpimtrostat inhibits PPT1, dysregulates lysosomal function, redistributes mTOR, and induces apoptosis. Ezurpimtrostat reduces IFN‑α, CRP, immune complex deposition, and SARS‑CoV‑2 viral load. Ezurpimtrostat can be used for the study of systemic lupus erythematosus, SARS‑CoV‑2, hepatocellular carcinoma, fibrosis, and related disorders [1] .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P71230
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: Palmitoyl-protein thioesterase 1; PPT-1; Palmitoyl-protein hydrolase 1; PPT1
Species:  
Source:  
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P700622
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: Palmitoyl-protein thioesterase 1; PPT-1; Palmitoyl-protein hydrolase 1; PPT1
Species:  
Source:  
loading...
    loading...
Cat. No.: HY-120252
CAS No.: 1831135-46-6
Purity:  98.7%
Target:  

Ser/Thr Protease

Research Areas:  

Neurological Disease

ABC44 is a potent serine hydrolase inhibitor with IC50s of 0.1 μM and 6.5 μM for palmitoyl protein thioesterase 1 (PPT1) in situ and in vitro, respectively. ABC44 can be used for researching infantile neuronal ceroid lipofuscinosis [1].
loading...
    loading...
Cat. No.: HY-RS11038
Research Areas:  

Others

PPT1 Human Pre-designed siRNA Set A contains three designed siRNAs for PPT1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-RS17296
Research Areas:  

Others

Ppt1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ppt1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-170670
CAS No.: 2027551-01-3
Target:  

Autophagy mTOR

Research Areas:  

Cancer

DQ661 is a potent PPT1 inhibitor. DQ661 is a dimeric quinacrine autophagy inhibitor. DQ661 inhibits mTORC1 activity. DQ661 decreases the protein expression of pS6K T389, pS6 S240-244. DQ661 shows anticancer activity [1] .
loading...
    loading...
Cat. No.: HY-RS23751
Research Areas:  

Others

Ppt1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ppt1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-P88201
Synonyms: CLN1; INCL; PPT

Host:  

Mouse

Application:  

WB, IHC-P

Reactivity:  

Human

loading...
    loading...
Cat. No.: HY-P88201A
Synonyms: CLN1; INCL; PPT

Host:  

Mouse

Application:  

WB, IHC-P

Reactivity:  

Human, Dog, Monkey

loading...
    loading...
Cat. No.: HY-183351
Research Areas:  

Cancer

GN-604 is a targeted drug conjugate (Targeted Drug Conjugate, TDC) formed by conjugation of GNS561 (HY-137978) with DN604, a Pt (II) complex. GN-604 selectively inhibits PPT1, induces lysosomal dysfunction, suppresses autophagy and triggers apoptosis. GN-604 promotes the targeted sequestration of Pt (II) inside cells, induces DNA damage and inhibits the proliferation of malignant cells. GN-604 is applicable to research related to triple-negative breast cancer [1].
loading...
    loading...
  • 1